8-K filed Aug 17, 2026 at 08:30 ET
Fulcrum Therapeutics (FULC) entered into a definitive merger agreement to acquire Slate Medicines in a reverse-merger transaction. Fulcrum will issue shares to Slate stockholders at an exchange ratio based on a $350M company valuation (plus a concurrent $245M PIPE investment), while Fulcrum is valued at $31.3M. The combined company will operate as Slate Medicines, with Slate's management taking control. Fulcrum stockholders will receive a pre-closing cash dividend of excess net cash above $20.3M. The deal requires shareholder approval and HSR clearance, with a February 28, 2027 outside date. This is a transformative event that effectively hands control to Slate, making FULC a new entity with a new pipeline and substantial cash from the PIPE.